Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspire Health vs GoodRx

Aspire Health
Graded #346

Lower grade

vs+10.399999999999991
GoodRx
Graded #122

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 59.2/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +35
45
80
Dose & formulationGoodRx +17
53
70
Clinical oversightAspire Health +15
84
69
Labs & monitoringAspire Health +15
66
51
FulfillmentGoodRx +20
61
81
Contract termsGoodRx +14
41
55
Aspire Health · left barGoodRx · right bar

The numbers

MetricAspire HealthGoodRx
WeighScore59.2/10069.6/100
GradeCC
Scorecard rank#346#122
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosed$299/mo (brand Zepbound)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Aspire Health

Graded #346 · C

Strengths

  • Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
  • Lab orders with interpretation included in LoseIt membership — not billed separately
  • Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
  • Slimpossible app + secure messaging for ongoing support between provider visits
  • HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans

Where it loses points

  • Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
  • No LegitScript certification or independent third-party accreditation disclosed
  • States served not publicly listed; availability depends on individual provider licensure
  • All medication sales are final once shipped; consultation fee non-refundable once completed
  • Compounding pharmacy partner not named on any public page
GoodRx

Graded #122 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard